Enhance MD vs Telos Rx: Semaglutide and Tirzepatide Pricing Guide
The comparison Enhance MD vs Telos Rx comes down to introductory pricing, flat-rate dose policy, compound availability, and enrollment terms. Quick verdict: if lowest first-month cost for either compound is your priority, Enhance MD shows the lowest advertised entry prices; if you prefer an advertised “as low as” monthly price with explicit cancellation terms, Telos Rx presents that option.
See Enhance MD starting at $49 first month
Overview: pricing statements and clinician review
Both providers offer compounded semaglutide and tirzepatide prescribed only after review by a licensed clinician. The regulatory note for both is the same in the source: compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. That shared status is central to any direct comparison of Enhance MD vs Telos Rx.
Three distinctive differences between Enhance MD and Telos Rx
1) Advertised starting prices
Enhance MD advertises semaglutide from $49 and tirzepatide from $99 for the first month. Telos Rx advertises semaglutide as low as $99 per month and tirzepatide as low as $139 per month. Those starting-price statements are the clearest, supported pricing claims in each provider’s source material and are often decisive for cost-sensitive patients.
View Telos Rx pricing as low as $99
2) Pricing model and dose escalation
Enhance MD emphasizes flat-rate pricing: the same price at every dose with no fee escalation during titration and the lowest first-month price for both compounds. Telos Rx materials repeatedly note “as low as” pricing and state that your price depends on your plan; Telos Rx also highlights cancel anytime terms. The difference: Enhance MD highlights flat-rate stability once ongoing pricing is set; Telos Rx emphasizes variable pricing tied to approval and plan.
3) Transparency and enrollment caveats
Enhance MD cites concrete first-month numbers and calls out their 10,000+ patients treated figure in the source. Telos Rx warns readers to confirm eligibility, pharmacy, state coverage, and renewal terms before enrollment, and its source repeatedly notes pricing, eligibility, pharmacy, state coverage and renewal terms may change. That makes Telos Rx’s messaging more conditional in the captured evidence.
Side-by-side snapshot
| Criteria | Enhance MD | Telos Rx |
|---|---|---|
| Semaglutide starting price | Semaglutide from $49 first month | Semaglutide as low as $99 per month |
| Tirzepatide starting price | Tirzepatide from $99 first month | Tirzepatide as low as $139 per month |
| Pricing model | Flat-rate pricing: same price at every dose, no escalation | “As low as” pricing; price depends on plan and approval |
| Enrollment and approval | Clinician-directed review; treated 10,000+ patients | Prescribed only after review by a US-licensed provider; confirm eligibility |
| Regulatory note | Compounded medications are not FDA-approved | Compounded medications are not FDA-approved |
What the sources say about care and terms
Enhance MD presents clinician-directed metabolic care with both semaglutide and tirzepatide available on one platform and emphasizes a consistent price from first dose to last, plus metabolic lab testing every six months in captured materials. Telos Rx highlights that a US-licensed provider decides which molecule is right for you, notes that pay $0 if not approved language appears in captured text, and states cancel anytime, no penalties in its materials. Both sources stress clinician review and the compounded status of the medications.
Start Enhance MD enrollment from $49
Safety, regulatory, and coverage notes
Both providers’ captured materials include the same regulatory qualifier: compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Telos Rx explicitly tells readers to confirm eligibility, pharmacy, state coverage and renewal terms before enrollment. Enhance MD notes clinician-directed prescribing and that treatment is available only when a licensed clinician determines it is medically appropriate.
Conclusion: which to choose
In short, Enhance MD vs Telos Rx is largely a choice between lower advertised first-month entry prices and a flat-rate messaging from Enhance MD versus Telos Rx’s “as low as” monthly pricing and conditional enrollment language. Both require clinician review and both offer compounded semaglutide and tirzepatide.
Check Telos Rx terms and eligibility
Compare Enhance MD options and pricing
Choose Enhance MD if…
- You prioritize the lowest advertised first-month price: semaglutide from $49 and tirzepatide from $99 in the source.
- You prefer a flat-rate pricing model that the source describes as the same price at every dose with no escalation.
- You want access to both semaglutide and tirzepatide on one platform per the captured evidence.
Choose Telos Rx if…
- You want an “as low as” monthly price and explicit cancel anytime language in the source.
- You plan to confirm eligibility, pharmacy, state coverage and renewal terms before enrollment, as the source advises.